Association of asthma with polymorphisms in the cysteinyl leukotriene 2 receptor

Abstract

Polymorphisms in the cysteinyl-leukotriene receptor 2 gene and their association with asthma are described.

1. A method of identifying a subject at increased risk of asthma, comprising detecting the allelic forms of the A601G polymorphism in the Cysteinyl leukotriene 2 receptor gene, where a person homozygous for the A allele is at increased risk for asthma compared to a subject with at least one G allele. 
     
     
       2. A method according to  claim 1  where the subject is a member of a family having at least one member diagnosed with asthma. 
     
     
       3. A method of stratifying a population receiving pharmaceutical treatment for asthma to detect differences in phenotypic response to the pharmaceutical treatment, by:
 (a) genotyping a population of subjects in need of pharmaceutical treatment for asthma, to determine each subject's allelic forms of the A601G polymorphism in the Cysteinyl leukotrine 2 receptor gene;  
 (b) administering to said subjects a pharmaceutical treatment for asthma;  
 (c) correlating each subject's phenotypic response to treatment with the subject's genotype, to detect phenotypic responses that are associated with said allelic forms.